Perverse Incentives: Why Everyone Prefers High Drug Prices -- Except for Those Who Pay the Bills

Antibiotic resistance: who will pay the bills?

The rapid emergence of antimicrobial resistance among bacteria is a public health crisis. Infections with antimicrobial-resistant bacteria increase patient morbidity and mortality and greatly increase the cost of medical care [1–4]. The number of resistant bacteria and the diversity of molecular mechanisms of resistance have increased sharply in recent years [5, 6], but the development of newer...

Who will pay future hospital bills?

Perverse incentives in the Medicare prescription drug benefit.

This paper analyzes some of the perverse incentives that may arise under the current Medicare prescription drug benefit design. In particular, risk adjustment for a stand-alone prescription drug benefit creates perverse incentives for prescription drug plans when making coverage decisions and/or for pharmaceutical companies when setting prices. This problem is new in that it does not arise with...

Provenance Needs Incentives for Everyone

Despite fervent early adopters, a rich research community and top-down mandates requiring its use, digital provenance has not become a pervasive and mainstream technology. While technological barriers still exist, the provenance community also must address thorny nontechnical issues. In particular, for critical stakeholders, the cost (time, expenses) of using and maintaining a provenance system...

Response to peer commentaries: prevention for those who can pay

Genetic testing for medically actionable genetic conditions can potentially limit the incidence and societal burden of disease if asymptomatic individuals can convert knowledge of their risk into preventive ormitigating steps.However, the generally treatmentfocusedUS insurance system complicates reimbursement for preventive interventions. In ‘Prevention for those who can pay’, I examined insura...